Article PDF first page preview

First page of Biopsychosocial Factors and Pain Hypervigilance should be considered in the Interpretation of Disease Activity in Systemic Sclerosis

Objective: This study aimed to identify a pain phenotype associated with hypervigilance in systemic sclerosis (SSc) and to evaluate possible variables that influence pain hypervigilance symptoms. Methods: This cross-sectional, observational study included healthy controls (HCs) and SSc patients diagnosed with a score of 9 or higher according to the 2013 American College of Rheumatology-European League Against Rheumatism classification criteria. The pain hypervigilance symptoms were evaluated using the CS Inventory (CSI) questionnaire, while disease activity was assessed using the European Scleroderma Research Group Activity Index (EScSG-AI). The patients were classified based on CSI scores. Comparative analyses were conducted for clinical, sociodemographic, and biopsychosocial factors. Results: 51 SSc patients (92.2% female, mean age 50.54±13.16 years) and 45 HCs (88.9% female, mean age 52.62±10.4 years) were included. Education and monthly income were lower for SSc than HCs (p<0.05). The CSI score≥40 proportion was 56.9% in SSc and 15.6% in HCs (p<0.001). Depression-Anxiety-Stress Scale (DASS-21), Epworth Sleepiness Scale (ESS), Global Pittsburgh Sleep Quality Index (PSQI), and EuroQol Five-Dimensional Three-Level Questionnaire (EQ-5D-3L) scores were higher in SSc than HCs (p<0.05). In multiple linear regression analysis to determine predictors of CSI score≥40, the effective variable was EScSG-AI. In multivariate logistic regression analysis, educational level and global PSQI scores were factors associated with CSI score≥40 in SSc. Conclusions: CSI score was positively associated with depression, disease activity, stress, anxiety, and poor sleep quality, and negatively associated with education and economic status. Pain hypervigilance may affect organ involvement and functioning in SSc. Clinicians should examine its biopsychosocial components.

Journal Section:
Research Article
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial